ValuEngine upgraded shares of Cytosorbents (NASDAQ:CTSO) from a sell rating to a hold rating in a research note published on Tuesday morning.
Several other research firms also recently issued reports on CTSO. Maxim Group set a $12.00 price objective on Cytosorbents and gave the company a buy rating in a report on Monday, January 8th. B. Riley set a $11.00 price objective on Cytosorbents and gave the company a buy rating in a report on Friday, December 22nd. Finally, HC Wainwright reiterated a buy rating and issued a $13.00 price objective on shares of Cytosorbents in a report on Tuesday, November 21st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $10.60.
Shares of Cytosorbents (CTSO) opened at $7.80 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. Cytosorbents has a 1-year low of $3.30 and a 1-year high of $7.85.
In other Cytosorbents news, CFO Kathleen P. Bloch sold 32,400 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $7.30, for a total transaction of $236,520.00. Following the sale, the chief financial officer now owns 248,638 shares in the company, valued at approximately $1,815,057.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Vincent Capponi sold 4,000 shares of the company’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the chief operating officer now owns 271,062 shares in the company, valued at approximately $1,897,434. The disclosure for this sale can be found here. 5.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wealthcare Advisory Partners LLC purchased a new stake in Cytosorbents during the 3rd quarter worth about $365,000. PNC Financial Services Group Inc. increased its holdings in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares during the period. Finally, Fortaleza Asset Management Inc. increased its holdings in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after purchasing an additional 10,500 shares during the period. Institutional investors own 8.65% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ValuEngine Upgrades Cytosorbents (CTSO) to Hold” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2018/01/13/valuengine-upgrades-cytosorbents-ctso-to-hold.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.